Related Experiment Video
Updated: Jun 25, 2025
05:19
Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors
Published on: March 29, 2019
10.3K
Machine learning identifies the role of SMAD6 in the prognosis and drug susceptibility in bladder cancer
Ziang Chen1,2, Yuxi Ou1,2, Fangdie Ye1,2
1Department of Urology, Huashan Hospital, Fudan University, Shanghai, China.
Journal of Cancer Research and Clinical Oncology
|May 20, 2024
Summary
Researchers discovered two new bladder cancer subtypes. The gene SMAD6 was identified as a key factor influencing prognosis and promoting better outcomes by inhibiting cancer cell growth and migration.
Area of Science:
- Oncology
- Molecular Biology
- Bioinformatics
Background:
- Bladder cancer (BCa) is a prevalent malignancy with high recurrence rates.
- Standard treatments like surgery have limited impact on patient prognosis.
- Novel therapeutic targets are needed for improved BCa treatment.
Purpose of the Study:
- To predict prognosis and identify therapeutic targets for bladder cancer.
- To uncover novel subtypes of bladder cancer based on molecular characteristics.
- To investigate the role of the TGF-β signaling pathway in bladder cancer.
Main Methods:
- Unsupervised clustering of TCGA-BLCA samples based on TGF-β pathway genes.
- Machine learning classifiers to identify key genes.
- Single-cell transcriptome analysis and in vitro assays.
- Analysis of SMAD6 and immune checkpoint gene interactions.
Main Results:
- Identified two distinct bladder cancer subtypes (C1 and C2) with differing biological characteristics.
- C1 subtype shows worse prognosis, lower drug sensitivity, and a 'colder' immune microenvironment.
- SMAD6 identified as a crucial gene; its inhibition of proliferation and migration promotes better BCa patient prognosis.
Conclusions:
- The study reveals two novel subtypes of bladder cancer.
- SMAD6 is identified as a promising therapeutic target for bladder cancer treatment.
